Cathyryne K. Manner, Ph.D.
Affiliations: | 2003 | University of California, San Diego, La Jolla, CA |
Area:
Molecular Biology, Neuroscience Biology, Oncology, PathologyGoogle:
"Cathyryne Manner"Mean distance: 42746.4
Parents
Sign in to add mentor| Carol L. MacLeod | grad student | 2003 | UCSD | |
| (The consequences of CAT2 arginine transporter ablation in cancer and neuropathology.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Davie SA, Maglione JE, Manner CK, et al. (2007) Effects of FVB/NJ and C57Bl/6J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient mice. Transgenic Research. 16: 193-201 |
| Ellies LG, Fishman M, Hardison J, et al. (2003) Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase. International Journal of Cancer. Journal International Du Cancer. 106: 1-7 |
| Manner CK, Nicholson B, MacLeod CL. (2003) CAT2 arginine transporter deficiency significantly reduces iNOS-mediated NO production in astrocytes. Journal of Neurochemistry. 85: 476-82 |
| Nicholson B, Manner CK, MacLeod CL. (2002) Cat2 L-arginine transporter-deficient fibroblasts can sustain nitric oxide production. Nitric Oxide : Biology and Chemistry / Official Journal of the Nitric Oxide Society. 7: 236-43 |
| Maglione JE, Moghanaki D, Young LJ, et al. (2001) Transgenic Polyoma middle-T mice model premalignant mammary disease. Cancer Research. 61: 8298-305 |
| Nicholson B, Manner CK, Kleeman J, et al. (2001) Sustained nitric oxide production in macrophages requires the arginine transporter CAT2. The Journal of Biological Chemistry. 276: 15881-5 |